According to the domestic chemical drug market analysis report released by the authoritative investigation agency, the economic operation of the chemical pharmaceutical industry in 2013 is not optimistic, but the growth is still worth looking forward to. Innovative enterprises will drive the transformation and upgrading of this industry. In addition, with the development of electronic business in the chemical and pharmaceutical industry, the entry into the trading platform has become the only way for innovative companies. The development of traditional APIs is limited, and transformation and upgrading need to be chosen. As Shenzhen innovative enterprises enter the southern trading platform, more and more API suppliers have begun their own e-commerce road.
China is a major producer of APIs. In 2012, the output of APIs was 1.36 million tons, an increase of 9.05% year-on-year, and production ranked first in the world. The economies of scale benefited from the low cost and environmental pollution produced in China. At present, China's prices generally rise and environmental management continues to strengthen, the cost advantage of industry development becomes less obvious.
Internationally, China's largest competitor, India, although its scale of development in the industry is not as good as China's, but it has obvious advantages over China in terms of cost advantages and industry development speed.